We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that GoodRx Holdings, Inc. (GDRX - Free Report) will report quarterly earnings of $0.09 per share in its upcoming release, pointing to a year-over-year increase of 12.5%. It is anticipated that revenues will amount to $199.81 million, exhibiting an increase of 1.6% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some GoodRx metrics that Wall Street analysts commonly model and monitor.
The consensus estimate for 'Revenue- Prescription transactions' stands at $143.21 million. The estimate indicates a change of -0.5% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Other' will reach $5.19 million. The estimate points to a change of -0.7% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Pharma Manufacturer Solutions' will reach $29.57 million. The estimate points to a change of +21.2% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- Subscription' reaching $21.83 million. The estimate points to a change of -5.7% from the year-ago quarter.
Analysts predict that the 'Monthly Active Consumers' will reach 7. Compared to the current estimate, the company reported 6 in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Subscribers plans' will likely reach 702. The estimate is in contrast to the year-ago figure of 884.
Over the past month, GoodRx shares have recorded returns of -0.2% versus the Zacks S&P 500 composite's -1.8% change. Based on its Zacks Rank #3 (Hold), GDRX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics
Wall Street analysts forecast that GoodRx Holdings, Inc. (GDRX - Free Report) will report quarterly earnings of $0.09 per share in its upcoming release, pointing to a year-over-year increase of 12.5%. It is anticipated that revenues will amount to $199.81 million, exhibiting an increase of 1.6% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some GoodRx metrics that Wall Street analysts commonly model and monitor.
The consensus estimate for 'Revenue- Prescription transactions' stands at $143.21 million. The estimate indicates a change of -0.5% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Other' will reach $5.19 million. The estimate points to a change of -0.7% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Pharma Manufacturer Solutions' will reach $29.57 million. The estimate points to a change of +21.2% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- Subscription' reaching $21.83 million. The estimate points to a change of -5.7% from the year-ago quarter.
Analysts predict that the 'Monthly Active Consumers' will reach 7. Compared to the current estimate, the company reported 6 in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Subscribers plans' will likely reach 702. The estimate is in contrast to the year-ago figure of 884.
View all Key Company Metrics for GoodRx here>>>
Over the past month, GoodRx shares have recorded returns of -0.2% versus the Zacks S&P 500 composite's -1.8% change. Based on its Zacks Rank #3 (Hold), GDRX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>